SlideShare une entreprise Scribd logo
1  sur  84
Télécharger pour lire hors ligne
Tratamientos sistémicos en el NSCLC

ANTIANGIOGÉNICOS

Dr J Pérez Altozano
HGU Elche / H Vega Baja Orihuela
8 de noviembre de 2013
History of Therapy in Advanced
NSCLC: FDA Approval Dates
Gefitinib
2003

Docetaxel
2002

Standard therapies
First line
Second line
Third line
Maintenance
Not approved

Cisplatin
1978

Carboplatin
1989

BSC

Paclitaxel
Gemcitabine
1998

Bevacizumab
2006
Pemetrexed
2008/2009

Vinorelbine
1994

12+

Median
OS (mos)

~ 8-10
~6

~ 2-4

1970

Erlotinib
Pemetrexed
2004

Docetaxel
1999

1980
Single-agent platinum

1990

2000

Bevacizumab + PC

Doublets
Histology-directed therapy

1. FDA Web site. 2. NCCN. Clinical practice guidelines in oncology. v.3.2011. 3. Schrump, et al. Non-small
cell lung cancer. In: Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott
Williams & Wilkins; 2005.
Incidence of NSCLC
Histologic Subtypes

20%
40%
15%
30%

Adenocarcinoma
Squamous-cell carcinoma
Large-cell carcinoma
NOS
Lung Cancer Molecular Consortium
Analysis in Lung Adenocarcinomas
No Mutation
Detected

AKT1
NRAS
MEK1
MET AMP
HER2
PIK3CA 2%
BRAF 2%
Double
Mutants 3%

EML4-AKL
7%

KRAS
22%
EGFR
17%

Kris MG, et al. ASCO 2011. CRA7506. Johnson BE, et al. IASLC WCLC 2011. Abstract O16.01
EGFR
HER2

KRAS

VEGF
VEGFR
BRAF

EML4ALK
Index
• Bevacizumab
• Antiangiogenic TKIs
• Upcoming targeted therapies
Bevacizumab
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
Background
Evaluate the feasibility of induction combination therapy with cisplatin, pemetrexed and bevacizumab followed by surgery in patients
with clinical stage II/IIIA nonsquamous NSCLC.

Methods
Induction chemotherapy : 3 cycles of cisplatin (75 mg/m2), pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) on Day 1,
every 21 days.
Patients underwent surgical resection at least 6 weeks after the last administration of bevacizumab,
Primary endpoint: complete resection rate after the completion of three cycles of induction chemotherapy.
Feasibility: complete resection rate 80% (24/30) or more.

Results
6 institutions in Japan, June 2010 - November 2012.
31 patients were recruited, 30 of which were eligible.
Median age was 64 years (range: 54-71).
Adenocarcinoma/large cell carcinoma ratio: 30/0
Clinical stage IIA/IIB/IIIA ratio: 5/3/22.
Grade 3 toxicities: Neutropenia (7%), nausea (7%), appetite loss (13%), hypertension (23%) and pulmonary embolism (3%).
27 (90%) patients completed three cycles at the full dose of chemotherapy.
CR in 0%, PR in 37%, SD in 50% and PD in 10%. Disease control rate (CR+PR+SD) 87%.
Five patients dropped out from the study before surgery.
Complete resection rate after the completion of three cycles of induction chemotherapy: 83% (25/80).

Conclusion
Induction chemotherapy using a combination of cisplatin, pemetrexed and bevacizumab in patients with resectable clinical stage II/IIIA
nonsquamous NSCLC is therefore considered to be a feasible treatment modality.
Background
Evaluate the feasibility of induction combination therapy with cisplatin, pemetrexed and bevacizumab followed by surgery in patients
with clinical stage II/IIIA nonsquamous NSCLC.

Methods
Induction chemotherapy : 3 cycles of cisplatin (75 mg/m2), pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) on Day 1,
every 21 days.
Patients underwent surgical resection at least 6 weeks after the last administration of bevacizumab,
Primary endpoint: complete resection rate after the completion of three cycles of induction chemotherapy.
Feasibility: complete resection rate 80% (24/30) or more.

Results
6 institutions in Japan, June 2010 - November 2012.
31 patients were recruited, 30 of which were eligible.
Median age was 64 years (range: 54-71).
Adenocarcinoma/large cell carcinoma ratio: 30/0
Clinical stage IIA/IIB/IIIA ratio: 5/3/22.
Grade 3 toxicities: Neutropenia (7%), nausea (7%), appetite loss (13%), hypertension (23%) and pulmonary embolism (3%).
27 (90%) patients completed three cycles at the full dose of chemotherapy.
CR in 0%, PR in 37%, SD in 50% and PD in 10%. Disease control rate (CR+PR+SD) 87%.
Five patients dropped out from the study before surgery.
Complete resection rate after the completion of three cycles of induction chemotherapy: 83% (25/80).

Conclusion
Induction chemotherapy using a combination of cisplatin, pemetrexed and bevacizumab in patients with resectable clinical stage II/IIIA
nonsquamous NSCLC is therefore considered to be a feasible treatment modality.
Background
Explore the role of bevacizumab in the neoadjuvant setting.
Assess the safety and efficacy of neoadjuvant bevacizumab plus pemetrexed and carboplatin followed by surgery in
conventionally unresectable, locally advanced (III A-bulky N2, III B) lung adenocarcinoma.

Methods
Single-center, single-arm, phase II study investigates neoadjuvant bevacizumab (7.5mg/kg) plus pemetrexed (500 mg/m2) and
carboplatin (AUC=5) x 4 cycles followed by surgery scheduled 3-4 weeks after last neoadjuvant therapy.
Primary and secondary endpoints were resectability rate and perioperative complications.

Results
20 patients were enrolled.
Neoadjuvant-related toxicities: Epistaxis (5%), fatigue (30%), infusion reaction (5%), nausea (5%), diarrhea (10%), insomnia
(5%), headache (5%); neutropenia (25%), anemia (10%), thrombocytopenia (5%).
Grade > 3 toxicities: Fatigue (10%); neutropenia (5%), thrombocytopenia (5%).
CR in 1 patient, PR in 8, SD in 10 and PD in 1.
14 (70%) patients underwent surgery.
Median time between last neoadjuvant therapy and surgery: 25 days (22-28).
R0 resection achieved in 10 patients.
Postoperative complications were manageable.

Conclusion
The treatment modality of neoadjuvant bevacizumab plus pemetrexed and carboplatin followed by surgery appears to be safe
and feasible in patients with unresectable, locally advanced (III A-bulky N2, III B) lung adenocarcinoma.
Background
Explore the role of bevacizumab in the neoadjuvant setting.
Assess the safety and efficacy of neoadjuvant bevacizumab plus pemetrexed and carboplatin followed by surgery in
conventionally unresectable, locally advanced (III A-bulky N2, III B) lung adenocarcinoma.

Methods
Single-center, single-arm, phase II study investigates neoadjuvant bevacizumab (7.5mg/kg) plus pemetrexed (500 mg/m2) and
carboplatin (AUC=5) x 4 cycles followed by surgery scheduled 3-4 weeks after last neoadjuvant therapy.
Primary and secondary endpoints were resectability rate and perioperative complications.

Results
20 patients were enrolled.
Neoadjuvant-related toxicities: Epistaxis (5%), fatigue (30%), infusion reaction (5%), nausea (5%), diarrhea (10%), insomnia
(5%), headache (5%); neutropenia (25%), anemia (10%), thrombocytopenia (5%).
Grade > 3 toxicities: Fatigue (10%); neutropenia (5%), thrombocytopenia (5%).
CR in 1 patient, PR in 8, SD in 10 and PD in 1.
14 (70%) patients underwent surgery.
Median time between last neoadjuvant therapy and surgery: 25 days (22-28).
R0 resection achieved in 10 patients.
Postoperative complications were manageable.

Conclusion
The treatment modality of neoadjuvant bevacizumab plus pemetrexed and carboplatin followed by surgery appears to be safe
and feasible in patients with unresectable, locally advanced (III A-bulky N2, III B) lung adenocarcinoma.
Background
Two combination chemotherapy regimens were compared in a Phase 3, randomized, open-label United States only study

Methods
Stage IV chemonaïve non-squamous NSCLC.
PemC (n=182) or PCB (n=179).
Safety data compared for patients who received ≥1 dose of study treatment (PemC:171; PCB:166), and resource use including
concomitant medications, transfusions, and hospitalizations was recorded.

Results
PemC experienced significantly more drug-related Grade 3/4 anemia (18.7% vs. 5.4%; p<0.001), Grade 3/4 thrombocytopenia (24.0% vs.
9.6%; p<0.001), and Grade 1/2 nausea (46.8% vs. 28.9%; p<0.001)
PCB experienced significantly more drug-related Grade 3/4 neutropenia (24.6% vs. 48.8%; p<0.001) and Grade 1/2 alopecia (8.2% vs.
28.3%; p<0.001).
Patients on PemC required more red blood cell (RBC) transfusions (34.5% vs. 11.4%; p<0.001).
Erythropoietic stimulating agents (ESAs) were used more frequently (19.9% vs. 7.2%; p<0.001) in PemC.
Granulocyte colony-stimulating factor (G-CSF) use was significantly higher with PCB (17.0% vs. 30.1%; p=0.005).

Conclusion
Mild-to-moderate nausea more common for PemC and alopecia, infection and neuropathy more frequent for PCB.
Hospitalizations did not differ between treatments.
ESAs and RBC transfusions were more common with PemC, and G-CSF use was more common with PCB.
Background
Two combination chemotherapy regimens were compared in a Phase 3, randomized, open-label United States only study

Methods
Stage IV chemonaïve non-squamous NSCLC.
PemC (n=182) or PCB (n=179).
Safety data compared for patients who received ≥1 dose of study treatment (PemC:171; PCB:166), and resource use including
concomitant medications, transfusions, and hospitalizations was recorded.

Results
PemC experienced significantly more drug-related Grade 3/4 anemia (18.7% vs. 5.4%; p<0.001), Grade 3/4 thrombocytopenia (24.0% vs.
9.6%; p<0.001), and Grade 1/2 nausea (46.8% vs. 28.9%; p<0.001)
PCB experienced significantly more drug-related Grade 3/4 neutropenia (24.6% vs. 48.8%; p<0.001) and Grade 1/2 alopecia (8.2% vs.
28.3%; p<0.001).
Patients on PemC required more red blood cell (RBC) transfusions (34.5% vs. 11.4%; p<0.001).
Erythropoietic stimulating agents (ESAs) were used more frequently (19.9% vs. 7.2%; p<0.001) in PemC.
Granulocyte colony-stimulating factor (G-CSF) use was significantly higher with PCB (17.0% vs. 30.1%; p=0.005).

Conclusion
Mild-to-moderate nausea more common for PemC and alopecia, infection and neuropathy more frequent for PCB.
Hospitalizations did not differ between treatments.
ESAs and RBC transfusions were more common with PemC, and G-CSF use was more common with PCB.
Background
Two combination chemotherapy regimens were compared in a Phase 3, randomized, open-label United States only study

Methods
Stage IV chemonaïve non-squamous NSCLC.
PemC (n=182) or PCB (n=179).
Safety data compared for patients who received ≥1 dose of study treatment (PemC:171; PCB:166), and resource use including
concomitant medications, transfusions, and hospitalizations was recorded.

Results
PemC experienced significantly more drug-related Grade 3/4 anemia (18.7% vs. 5.4%; p<0.001), Grade 3/4 thrombocytopenia (24.0% vs.
9.6%; p<0.001), and Grade 1/2 nausea (46.8% vs. 28.9%; p<0.001)
PCB experienced significantly more drug-related Grade 3/4 neutropenia (24.6% vs. 48.8%; p<0.001) and Grade 1/2 alopecia (8.2% vs.
28.3%; p<0.001).
Patients on PemC required more red blood cell (RBC) transfusions (34.5% vs. 11.4%; p<0.001).
Erythropoietic stimulating agents (ESAs) were used more frequently (19.9% vs. 7.2%; p<0.001) in PemC.
Granulocyte colony-stimulating factor (G-CSF) use was significantly higher with PCB (17.0% vs. 30.1%; p=0.005).

Conclusion
Mild-to-moderate nausea more common for PemC and alopecia, infection and neuropathy more frequent for PCB.
Hospitalizations did not differ between treatments.
ESAs and RBC transfusions were more common with PemC, and G-CSF use was more common with PCB.
Background
Designed on preclinical results suggesting additive interaction of metronomic chemotherapy with VEGF deprivation and EGFR
inhibition, in term of anti-tumor/anti-angiogenic-activity and immune-modulation.

Methods
35 inoperable NSCLC patients. 26 adenocarcinoma, 6 squamocellular and 3 NAS carcinoma.
Median age of 68 years (range 3-75).
Cisplatin (30mg/sqm days 1-3q21 + Etoposide 50mg/sqm days 1-15/21 + Bevacizumab 5mg/kg on the day 3q21.
After 4 treatment courses, all patients who achieved a PR or SD received daily Erlotinib (150 mg/day), starting 1 week after end of
chemotherapy until PD.
Cytokine multiplex analysis and an immune-cytofluorimetric analysis after 4 bio-chemotherapy courses and 3 months after end of biochemotherapy.

Results
Significant decrease in serum levels of VEGF and IL-10 which was maintained along TKI treatment.
No change in angiopoietin, interferon gamma, IL-12, PECAM and follistatin levels.
During TKI maintenance we recorded an increase in IL-8 and leptine associated with a significant decrease in G-CSF levels and
angiopoietin levels.
Our immune-cytofluorimetric analysis of patients’ PBMCs showed a significant treatment-related increase in activated (CD3CD11C+CD14+CD80+CD83+) dendritic cells and activated (CD3+CD8+CD62L+) cytotoxic-T –lymphocytes.

Conclusion
Treatment strategy is safe and active in NSCLC patients, and is able to affects their systemic inflammatory status also inducing immunemodulation with potential antitumor.
Background
Designed on preclinical results suggesting additive interaction of metronomic chemotherapy with VEGF deprivation and EGFR
inhibition, in term of anti-tumor/anti-angiogenic-activity and immune-modulation.

Methods
35 inoperable NSCLC patients. 26 adenocarcinoma, 6 squamocellular and 3 NAS carcinoma.
Median age of 68 years (range 3-75).
Cisplatin (30mg/sqm days 1-3q21 + Etoposide 50mg/sqm days 1-15/21 + Bevacizumab 5mg/kg on the day 3q21.
After 4 treatment courses, all patients who achieved a PR or SD received daily Erlotinib (150 mg/day), starting 1 week after end of
chemotherapy until PD.
Cytokine multiplex analysis and an immune-cytofluorimetric analysis after 4 bio-chemotherapy courses and 3 months after end of biochemotherapy.

Results
Significant decrease in serum levels of VEGF and IL-10 which was maintained along TKI treatment.
No change in angiopoietin, interferon gamma, IL-12, PECAM and follistatin levels.
During TKI maintenance we recorded an increase in IL-8 and leptine associated with a significant decrease in G-CSF levels and
angiopoietin levels.
Our immune-cytofluorimetric analysis of patients’ PBMCs showed a significant treatment-related increase in activated (CD3CD11C+CD14+CD80+CD83+) dendritic cells and activated (CD3+CD8+CD62L+) cytotoxic-T –lymphocytes.

Conclusion
Treatment strategy is safe and active in NSCLC patients, and is able to affects their systemic inflammatory status also inducing immunemodulation with potential antitumor.
Background
Frequent administration of low dose chemotherapy agents (metronomic chemotherapy [MC]) is thought to target endothelial
cells of the tumor vasculature as well as tumor cells.
Pilot phase 2 study: Bevacizumab and MC will result in enhanced antiangiogenic effect and clinical benefit in advanced NSCLC.

Methods
Untreated patients with stage 4 non-squamous NSCLC.
4-week cycle of paclitaxel (80 mg/m2 D1, 8, 15), gemcitabine (200-300 mg/m2 D1, 8, 15) and bevacizumab (10 mg/kg D1, 15)
for 6 cycles. Patients without progressive disease received maintenance bevacizumab every 2 weeks.
Primary endpoint: PFS with the goal to achieve a 30% improvement in the 6.4 months.
Secondary endpoints: ORR, OS, safety and evaluation of potential biomarkers of angiogenesis.

Results
33 evaluable patients were enrolled
Median age 59 years.
Grade 3 neutropenia (15%); grade 3 fatigue (6%); grade 3 nausea (3%); grade 3/4 hypertension (30%); grade 3/4 proteinuria
(18%); pneumonitis (3 patients); and ischemic events (2 patients).
Baseline biomarkers with significant correlation with response parameters: VEGF2 (ORR); PLGF (OS); angiopoietin -2 (PFS, OS);
endocan (ORR); IL-8 (ORR, PFS); TGFβ-1 (ORR); thrombospondin-1 (ORR); and angiopoietin-1 (ORR).
PFS: 9m (95% CI:7; 10), OS 30m (95% CI: 18; 37), 1-year survival rate 74%, 2-year survival rate 55%, ORR 73% (95% CI:0.54;
0.87)

Conclusion
MC with a platinum doublet in combination with bevacizumab is a feasible, tolerable, and active regimen in advanced nonsquamous NSCLC. Potential biomarkers were correlated with clinical outcome.
Background
Prospective phaseⅡ study to evaluate the efficacy and safety of bevacizumab in combination with carboplatin and
paclitaxel(PCB) for EGFR-TKIs resistant Non-Sq NSCLC.

Methods
Multicenter phase II trial.
Non-squamous NSCLC harboring EGFR gene mutation after failing EGFR-TKIs.
Patients received carboplatin (AUC=6/5), paclitaxel (200mg/m2), bevacizumab (15mg/kg) intravenously on day1 every 3
weeks for three to six cycles, and bevacizumab every 3 weeks until disease progression or intolerable toxic effects.
Primary endpoint: RR
Secondary endpoints: PFS, OS, disease control rate and safety.

Results
30 patients between March 2010 - February 2013.
Median age: 60 years (45~74).
EGFR mutation status exon19 del/exon21 L858R : 20/11.
1st line EGFR-TKIs gefitinib/erlotinib/other : 22/7/1.
RR : 40% (95%CI:22%-58%).
DCR : 83% (95%CI:70%-97%), PFS : 6.0 month (95%CI:4.8-12.2).

Conclusion
RR of 2nd line PCB therapy was lower than it was in 1st line phase II study of PCB in Japan, but same RR of E4599 study.
We considered PCB therapy is one of the treatment option in 2nd-line for patient with EGFR-TKIs resistant Non-Sq NSCLC.
Background
Prospective phaseⅡ study to evaluate the efficacy and safety of bevacizumab in combination with carboplatin and
paclitaxel(PCB) for EGFR-TKIs resistant Non-Sq NSCLC.

Methods
Multicenter phase II trial.
Non-squamous NSCLC harboring EGFR gene mutation after failing EGFR-TKIs.
Patients received carboplatin (AUC=6/5), paclitaxel (200mg/m2), bevacizumab (15mg/kg) intravenously on day1 every 3
weeks for three to six cycles, and bevacizumab every 3 weeks until disease progression or intolerable toxic effects.
Primary endpoint: RR
Secondary endpoints: PFS, OS, disease control rate and safety.

Results
30 patients between March 2010 - February 2013.
Median age: 60 years (45~74).
EGFR mutation status exon19 del/exon21 L858R : 20/11.
1st line EGFR-TKIs gefitinib/erlotinib/other : 22/7/1.
RR : 40% (95%CI:22%-58%).
DCR : 83% (95%CI:70%-97%), PFS : 6.0 month (95%CI:4.8-12.2).

Conclusion
RR of 2nd line PCB therapy was lower than it was in 1st line phase II study of PCB in Japan, but same RR of E4599 study.
We considered PCB therapy is one of the treatment option in 2nd-line for patient with EGFR-TKIs resistant Non-Sq NSCLC.
Background
Interim-analysis result of the BEST trial.
Examines efficacy and safety of second- or third-line chemotherapy with erlotinib (E) and bevacizumab (B) for the Japanese patients
(pts) with non-squamous, non-small cell lung cancer.

Methods
E 150 mg/day orally + B 15 mg/kg on the first day of each 3-week cycle.
Primary endpoint: RR.
Secondary endpoints: OS, PFS, disease control rate and incidence of adverse events.
Planned to accrue 80 pts based on a two-stage design employing a binomial distribution with an alternative hypothesis response rate
of 35% and a null hypothesis threshold response rate of 20%.

Results
28 pts enrolled in 2 years.
Median age: 67y (43-82).
All had adenocarcinoma; 11 pts had EGFR mutation.
1 patient had stage IIIB, 23 pts had stage IV and 3 pts had recurrences after surgery.
21 pts received as second-line and 6 pts received as third-line chemotherapy.
RR 18.5% (p=1.00; one-sided).
DCR 77.8%, PFS 5.6 m; OS data not yet mature (median follow-up time was 11.9 m).
Grade 3/4 non-hematologic toxicities: Acne (11.1%) and hypertension (11.1%).
Significantly higher RR (p=0.02) and better PFS (p=0.03) in mutant group than in wild group. RR in mutant group was compared with
20% null hypothesis using the same binomial test (p=0.056).

Conclusion
Combination therapy of B + E had mild adverse effects but did not increase anti-cancer effect.
Background
Interim-analysis result of the BEST trial.
Examines efficacy and safety of second- or third-line chemotherapy with erlotinib (E) and bevacizumab (B) for the Japanese patients
(pts) with non-squamous, non-small cell lung cancer.

Methods
E 150 mg/day orally + B 15 mg/kg on the first day of each 3-week cycle.
Primary endpoint: RR.
Secondary endpoints: OS, PFS, disease control rate and incidence of adverse events.
Planned to accrue 80 pts based on a two-stage design employing a binomial distribution with an alternative hypothesis response rate
of 35% and a null hypothesis threshold response rate of 20%.

Results
28 pts enrolled in 2 years.
Median age: 67y (43-82).
All had adenocarcinoma; 11 pts had EGFR mutation.
1 patient had stage IIIB, 23 pts had stage IV and 3 pts had recurrences after surgery.
21 pts received as second-line and 6 pts received as third-line chemotherapy.
RR 18.5% (p=1.00; one-sided).
DCR 77.8%, PFS 5.6 m; OS data not yet mature (median follow-up time was 11.9 m).
Grade 3/4 non-hematologic toxicities: Acne (11.1%) and hypertension (11.1%).
Significantly higher RR (p=0.02) and better PFS (p=0.03) in mutant group than in wild group. RR in mutant group was compared with
20% null hypothesis using the same binomial test (p=0.056).

Conclusion
Combination therapy of B + E had mild adverse effects but did not increase anti-cancer effect.
Background
Irinotecan and bevacizumab are effective against non-small cell lung cancer (NSCLC) and synergism with non-cross-resistance has
been demonstrated in preclinical studies.

Methods
24 patients having heavily treated metastatic NSCLC between March 2011 -November 2012.
16 patients had never been exposed to bevacizumab and 8 had received antiangiogenic therapy as part of their first-line (all had
achieved a previous response for more than 6 months).
90-min intravenous infusion of 125 mg/m2 irinotecan on day 1 and 8 + 7.5 mg/kg bevacizumab on day 1 every 3 weeks.

Results
1 patient (4.2%) CR, 6 (25%) PR.
ORR 29.2% (4.6 months median response duration).
7 patients SD and DCR was 58.3%.
PFS 4.8 months (95%CI 1.8-9.2) and OS 19.8 months (95%CI 9.2-30.2).
Grade 3-4 neutropenia in 43% of patients and thrombocytopenia in 8.3%.
4 patients harbouring EGFR mutations had a long-lasting, partial response (>7 months after at least 4 prior lines).
Conclusion
Favourable activity and manageable toxicity profiles as third or fourth line.
Regimen can represent a reasonable chemotherapeutic option, especially for subjects having EGFR mutations.
Background
Irinotecan and bevacizumab are effective against non-small cell lung cancer (NSCLC) and synergism with non-cross-resistance has
been demonstrated in preclinical studies.

Methods
24 patients having heavily treated metastatic NSCLC between March 2011 -November 2012.
16 patients had never been exposed to bevacizumab and 8 had received antiangiogenic therapy as part of their first-line (all had
achieved a previous response for more than 6 months).
90-min intravenous infusion of 125 mg/m2 irinotecan on day 1 and 8 + 7.5 mg/kg bevacizumab on day 1 every 3 weeks.

Results
1 patient (4.2%) CR, 6 (25%) PR.
ORR 29.2% (4.6 months median response duration).
7 patients SD and DCR was 58.3%.
PFS 4.8 months (95%CI 1.8-9.2) and OS 19.8 months (95%CI 9.2-30.2).
Grade 3-4 neutropenia in 43% of patients and thrombocytopenia in 8.3%.
4 patients harbouring EGFR mutations had a long-lasting, partial response (>7 months after at least 4 prior lines).
Conclusion
Favourable activity and manageable toxicity profiles as third or fourth line.
Regimen can represent a reasonable chemotherapeutic option, especially for subjects having EGFR mutations.
Background
Feasibility of BEV in NonSq-NSCLC patients who were previously treated with a platinum regimen.

Methods
Recurrent NonSq-NSCLC.
VNR (25mg/kg on day 1, 8) + BEV (15mg/kg, day 1) every 3 weeks until PD.
Primary endpoint: Feasibility.
Secondary endpoints: Response rate and safety.

Results
June 2011 - January 2013
15 NSCLC patients.
Median age: 68y (range 57-82).
Median of 4 (range 1-12) cycles.
Grade 3-4 neutropenia, anemia, thrombocytopenia and febrile neutropenia: 26.7%, 6.7%, 6.7%, and 13.3%.
RR 26.7% and disease control rate 73.3%.
PFS 2.8 months.
Grade 3-4 phlebitis occurred in 3 patients.

Conclusion
VNR + BEV was safe and effective in NonSq-NSCLC patients who were previously treated with a platinum
regimen.
Background
Feasibility of BEV in NonSq-NSCLC patients who were previously treated with a platinum regimen.

Methods
Recurrent NonSq-NSCLC.
VNR (25mg/kg on day 1, 8) + BEV (15mg/kg, day 1) every 3 weeks until PD.
Primary endpoint: Feasibility.
Secondary endpoints: Response rate and safety.

Results
June 2011 - January 2013
15 NSCLC patients.
Median age: 68y (range 57-82).
Median of 4 (range 1-12) cycles.
Grade 3-4 neutropenia, anemia, thrombocytopenia and febrile neutropenia: 26.7%, 6.7%, 6.7%, and 13.3%.
RR 26.7% and disease control rate 73.3%.
PFS 2.8 months.
Grade 3-4 phlebitis occurred in 3 patients.

Conclusion
VNR + BEV was safe and effective in NonSq-NSCLC patients who were previously treated with a platinum
regimen.
Background
Feasibility study of PEM plus BV as the first-line treatment for elderly advanced or recurrent non-Sq NSCLC.
Methods
Chemotherapy-naïve; unfit for bolus combination chemotherapy; stage III/IV or relapsed non-Sq NSCL.
Age≥70; PS 0-1; no evidence of brain metastasis; no history of hemoptysis and irradiation for thorax.
PEM (500mg/m2) + BV (15mg/kg) on day 1 every 3 weeks.
Primary endpoint: Toxicity
Secondary endpoints: ORR, PFS, OS and percentage of patients who completed more than 3 cycles.
Results
November 2010 -April 2012
12 patients.
Median age: 78 y (72-81).
Activating EGFR mutation No/Yes/unknown=9/2/1.
Stage IIIB/IV/Recurrence=2/8/2.
Grade 3≥ leukopenia (25%), neutropenia (25%), anemia (8%), thrombocytopenia (8%), febrile neutropenia (8%), anorexia (8%),
hypertension (8%), fatigue (8%), nausea (8%), and perforation (colon) (8%).
ORR 25%, PFS 5.6 (95% C.I. 1.1-7.9) and OS 10.3 months (95% C.I. 6.9-15.6 mo) in 11 evaluated patients.
1-year survival rate 49% (95% C.I. 12-79%).
7/12 pts (58%) received more than 3 cycles.
Conclusion
PEM +BV as first-line treatment for elderly non-Sq NSCLC was well tolerable and promising.
Background
Feasibility study of PEM plus BV as the first-line treatment for elderly advanced or recurrent non-Sq NSCLC.
Methods
Chemotherapy-naïve; unfit for bolus combination chemotherapy; stage III/IV or relapsed non-Sq NSCL.
Age≥70; PS 0-1; no evidence of brain metastasis; no history of hemoptysis and irradiation for thorax.
PEM (500mg/m2) + BV (15mg/kg) on day 1 every 3 weeks.
Primary endpoint: Toxicity
Secondary endpoints: ORR, PFS, OS and percentage of patients who completed more than 3 cycles.
Results
November 2010 -April 2012
12 patients.
Median age: 78 y (72-81).
Activating EGFR mutation No/Yes/unknown=9/2/1.
Stage IIIB/IV/Recurrence=2/8/2.
Grade 3≥ leukopenia (25%), neutropenia (25%), anemia (8%), thrombocytopenia (8%), febrile neutropenia (8%), anorexia (8%),
hypertension (8%), fatigue (8%), nausea (8%), and perforation (colon) (8%).
ORR 25%, PFS 5.6 (95% C.I. 1.1-7.9) and OS 10.3 months (95% C.I. 6.9-15.6 mo) in 11 evaluated patients.
1-year survival rate 49% (95% C.I. 12-79%).
7/12 pts (58%) received more than 3 cycles.
Conclusion
PEM +BV as first-line treatment for elderly non-Sq NSCLC was well tolerable and promising.
10 Antiangiogenicos en Cáncer de Pulmón
Background
A series of Japanese trials indicate docetaxel (DTX) monotherapy is a standard of care in elderly patients with advanced nonsmall cell lung cancer (NSCLC), and that the addition of platinum does not significantly improve the outcomes. BEV toxicity is a
major concern for elderly patients.

Methods
Chemotherapy-naïve patients with advanced non-squamous NSCLC >70 year old
ECOG PS 0/1 an
DTX 60 (Level 0) or 50 (Level -1) mg/m2 and BEV 15 mg/kg on day 1, every 3 weeks.
Primary endpoint: Toxicity
Secondary endpoints: ORR, PFS, OS and completion rate of the 3 cycles of treatment.

Results
December 2010 - September 2012.
21 elderly patients (9 in level 0 and 12 in level -1).
Median age: 75 years, 67% PS 1.
Grade 3 or 4 of toxicities among all patients: Neutropenia (86%), anemia (5%), hypertension (19%), anorexia (10%), and
increased aminotransferase levels (10%).
3/9 patients in level 0 and 3/11 patients in level -1 obtained PR.
Completion rates of the 3 cycles of treatment :78% (7/9) in level 0 and 67 % (8/12) in level -1.
Median PFS and OS: 5.4 and 11.1 months.

Conclusion
The recommended dose for this combination in future study is docetaxel 50 mg/m2 and bevacizumab 15mg/kg.
Phase II trial: C (50 mg/m2), D (50 mg/m2), and B (10 mg/kg) every 2 weeks for up to 6 cycles, followed by B alone every
2 weeks until disease progression or unacceptable toxicity.
Primary efficacy endpoint: PFS Secondary endpoints: Safety profile, ORR, disease control rate and OS
32 patients enrolled.
Median age: 60 years (range 44-72; 28.1% > 65 years).
Adenocarcinoma (%): 84.
Median PFS: 6.4 months (95% CI, 4.2-8.7).
Among the 22 patients evaluable for response: ORR 63.6% and DCR 95.4%.

Combination: Bevacizumab (15 mg/kg), docetaxel (60 mg/m2) and carboplatin (AUC=6) on day 1 was administered every 3
weeks up to 6 cycles (induction phase). Bevacizumab maintenance therapy was performed until PD (maintenance phase).
Primary endpoint: PFS to prove superiority to previous standard chemotherapy (docetaxel and cisplatin).
40 patients enrolled and 39 patients analyzed.
Stage IV in 92%, EGFR mutations in 13% and unknown EGFR status in 8%.
Median age: 62 years.
Induction phase: 4 cycles in median (range: 1-6).
21 patients (54%) received maintenance phase with median 4 cycles (range: 2-24).
ORR of 74% (26/35) and median PFS of 6.4 months (95% CI: 4.8-9.9).
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
Antiangiogenic TKIs
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
Background
Evaluate the benefits and harms of AATKIs when added to chemotherapy for advanced NSCLC.
Methods
Systematic review of randomised controlled trials (RCTs) of AATKIs added to chemotherapy for advanced or metastatic NSCLC.
Electronic databases (MEDLINE/PubMed, EMBASE, The Cochrane Library) + conference proceedings from ASCO, ESMO, IASLC WCLC and
Clinical Trials Registries.
Primary endpoint: OS.
Secondary endpoints: PFS, ORR and (G≥3 CTCAE. Meta-analysis of the data was performed to obtain pooled hazard ratios (HR) for OS and
PFS, and pooled odds ratios (OR) for ORR and G≥3CTCAE.
Review Manager v5.2 software (Cochrane).

Results
15 RCTs involving 7904 patients with advanced NSCLC. Overall population (N = 7904)
Addition of AATKI to chemotherapy:
Prolonged OS (HR 0.93; 95% confidence interval [CI] 0.88, 0.99; P=0.02) and PFS (HR 0.83; 95% CI 0.79, 0.88; P<0.00001).
Increased ORR (OR 1.64, 95% CI 1.34, 2.02; P<0.00001) and G≥3CTCAEs (OR 1.78, 95% CI 1.41, 2.25; P<0.00001).
First line (N = 3867), prolonged PFS (HR 0.86; 95% CI 0.79, 0.93; P<0.0001) but not OS (HR 0.96; 95% CI 0.89, 1.05; P=0.38).
Second line (N=4037), prolonged both OS (HR 0.91; 95% CI 0.84, 0.98; P=0.02) and PFS (HR 0.80; 95% CI 0.74, 0.87; P<0.00001).
Greatest OS benefit in patients with adenocarcinoma (HR 0.85; 95% CI 0.75, 0.96, P=0.01) and receiving docetaxel (HR 0.89; 95% CI 0.81,
0.98; P=0.02).
Addition of AATKIs to second line pemetrexed did not improve OS (HR 0.95; 95% CI 0.79, 1.13; P=0.54) nor in patients with squamous
histology (HR 1.01; 95% CI 0.87, 1.16; P=0.92).

Conclusion
The addition of AATKIs to chemotherapy in patients with advanced NSCLC prolongs OS, PFS and increases ORR, at the expense of increased
toxicity. Greatest benefit is in second line, in adenocarcinomas and in patients receiving docetaxel.
Background
Sunitinib is an oral, selective multi-targeted tyrosine kinase inhibitor (TKI) with antiangiogenic and antitumor
activities.
Evaluate the efficacy and toxicity of this therapeutic strategy.

Methods
Retrospective review of 30 stage IV NSCLC patients who received sunitinib as salvage therapy in Shanghai Chest
hospital, from January 2009 until August 2011.
All patients previously treated with EGFR-TKIs.

Results
Median PFS: 1.25 months (95% CI: 0.90-1.9 months).
Median OS: 3.40 months (95% CI: 3.00-6.80 months).
Of the 29 patients eligible for efficacy evaluation, none PR.
ECOG PS is predictive of both PFS (p=0.001) and OS (p<0.001).
Hand-foot syndrome (53.3%), mucositis (40.0%), rash (36.7%) and diarrhea (33.3%) most commonly reported
adverse events.

Conclusion
Sunitinib treatment did not demonstrate overall clinical benefits to the EGFR-TKI pretreated NSCLC Chinese
patients.
Background
Sunitinib is an oral, selective multi-targeted tyrosine kinase inhibitor (TKI) with antiangiogenic and antitumor
activities.
Evaluate the efficacy and toxicity of this therapeutic strategy.

Methods
Retrospective review of 30 stage IV NSCLC patients who received sunitinib as salvage therapy in Shanghai Chest
hospital, from January 2009 until August 2011.
All patients previously treated with EGFR-TKIs.

Results
Median PFS: 1.25 months (95% CI: 0.90-1.9 months).
Median OS: 3.40 months (95% CI: 3.00-6.80 months).
Of the 29 patients eligible for efficacy evaluation, none PR.
ECOG PS is predictive of both PFS (p=0.001) and OS (p<0.001).
Hand-foot syndrome (53.3%), mucositis (40.0%), rash (36.7%) and diarrhea (33.3%) most commonly reported
adverse events.

Conclusion
Sunitinib treatment did not demonstrate overall clinical benefits to the EGFR-TKI pretreated NSCLC Chinese
patients.
Background
Sorafenib as well as mTOR inhibitors showed preliminary activity in KRAS mutated NSCLC.

Methods
Patients with relapsed solid tumors.
Escalating doses of everolimus from 2.5-10.0 mg daily p.o. in a 14 days run-in phase  Combination with a
fixed dose of sorafenib 400 mg bid p.o.
KRAS mutation status is determined by PCR based high resolution melting curve analysis (HRM) on DNA
extracted from FFPE material and validated using Sanger sequencing.

Results
19 patients were recruited. DLT was not reached.
MTD: 7.5 mg/day everolimus + 400 mg sorafenib.
The best treatment outcome on day 57 was stable disease in 11 patients.
Median PFS and OS were 3.7 and 5.5 months.
The extension phase in KRAS mutated NSCLC is currently ongoing.

Conclusion
Treatment of patients with relapsed solid tumors with the combination of 7.5 mg everolimus p.o. daily + 400
mg sorafenib p.o. bid is safe and feasible. Current results of an extension phase in KRAS mutated NSCLC
patients show preliminary clinical activity in this patient group with an unfavorable prognosis.
Background
Sorafenib as well as mTOR inhibitors showed preliminary activity in KRAS mutated NSCLC.

Methods
Patients with relapsed solid tumors.
Escalating doses of everolimus from 2.5-10.0 mg daily p.o. in a 14 days run-in phase  Combination with a
fixed dose of sorafenib 400 mg bid p.o.
KRAS mutation status is determined by PCR based high resolution melting curve analysis (HRM) on DNA
extracted from FFPE material and validated using Sanger sequencing.

Results
19 patients were recruited. DLT was not reached.
MTD: 7.5 mg/day everolimus + 400 mg sorafenib.
The best treatment outcome on day 57 was stable disease in 11 patients.
Median PFS and OS were 3.7 and 5.5 months.
The extension phase in KRAS mutated NSCLC is currently ongoing.

Conclusion
Treatment of patients with relapsed solid tumors with the combination of 7.5 mg everolimus p.o. daily + 400
mg sorafenib p.o. bid is safe and feasible. Current results of an extension phase in KRAS mutated NSCLC
patients show preliminary clinical activity in this patient group with an unfavorable prognosis.
Upcoming targeted therapies
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
10 Antiangiogenicos en Cáncer de Pulmón
Background
Motesanib is an orally administrated small molecule antagonist of VEGFR 1, 2, 3, and platelet-derived growth factor receptor
(PDGFR), and stem cell factor receptor (c-kit).

Methods
Stage IV/recurrent non-squamous NSCLC patients without prior chemotherapy.
Oral motesanib (125 mg) or placebo once daily in combination with paclitaxel (200 mg/m2) and carboplatin (AUC = 6) every 3 weeks
up to 6 cycles and continue motesanib or placebo.
ECOG PS 0-1
400 patients will be randomized in a double-blind 1:1 ratio to motesanib or placebo.
Stratification factors: EGFR mutation status, weight loss of ≥ 5% in the previous 6 months, and region.

Results
First evaluation by IDMC performed using the data as of 26 December 2012.
63 patients (Japanese; median age, 64.5 y).
All the blinded patients who received study treatment experienced AEs.
Grade 3 to 5 AEs were reported in 38 patients (60.3%)  Alopecia (63.5%), peripheral sensory neuropathy (57.1%), and decreased
appetite (50.8%).
7 patients had 8 serious AEs (SAEs)  cholecystitis, gastric ulcer haemorrhage, nausea, and upper gastrointestinal hemorrhage
1 treatment-related fatal AE (interstitial lung disease)

Conclusion
The first IDMC recommended continuation of the study after the review of unblinded data of 63 patients.
Updated safety data will be presented after the second IDMC (JapicCTI-121887).
GRACIAS

Contenu connexe

Tendances

Locally Advanced Nsclc
Locally Advanced NsclcLocally Advanced Nsclc
Locally Advanced Nsclcfondas vakalis
 
Prostate cancer asco 2020 updates
Prostate cancer asco 2020 updatesProstate cancer asco 2020 updates
Prostate cancer asco 2020 updatesmadurai
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
Multimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii NsclcMultimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii Nsclcfondas vakalis
 
Slide deck updates on cml (1)
Slide deck updates on cml (1)Slide deck updates on cml (1)
Slide deck updates on cml (1)madurai
 
Management of advanced prostate carcinoma
Management of advanced prostate carcinomaManagement of advanced prostate carcinoma
Management of advanced prostate carcinomaAnimesh Agrawal
 
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)European School of Oncology
 
New in management of hormone sensitive prostate cancer
New in management of  hormone sensitive prostate cancerNew in management of  hormone sensitive prostate cancer
New in management of hormone sensitive prostate cancerAlok Gupta
 
Role of Chemotherapy, Targeted therapy and Immunotherapy in NSCLC (Part II)
Role of Chemotherapy, Targeted therapy and Immunotherapy in NSCLC (Part II)Role of Chemotherapy, Targeted therapy and Immunotherapy in NSCLC (Part II)
Role of Chemotherapy, Targeted therapy and Immunotherapy in NSCLC (Part II)Mohammed Fathy
 
Immunotherapy maintenence for advanced urothelial cancer
Immunotherapy maintenence for advanced urothelial cancerImmunotherapy maintenence for advanced urothelial cancer
Immunotherapy maintenence for advanced urothelial cancerChandan K Das
 
Her2 ebc webinar
Her2 ebc webinarHer2 ebc webinar
Her2 ebc webinarmadurai
 
Astro annual meeting 2014 highlights
Astro annual meeting 2014 highlightsAstro annual meeting 2014 highlights
Astro annual meeting 2014 highlightsAjeet Gandhi
 
Gut talk
Gut talkGut talk
Gut talkmadurai
 
Cco Gi 2008 Cr Slideset
Cco Gi 2008 Cr SlidesetCco Gi 2008 Cr Slideset
Cco Gi 2008 Cr SlidesetEmad El-Nashar
 
Advances in Immunotherapy for Non-Small Cell Lung Cancer
Advances in Immunotherapy for Non-Small Cell Lung CancerAdvances in Immunotherapy for Non-Small Cell Lung Cancer
Advances in Immunotherapy for Non-Small Cell Lung Cancerflasco_org
 
Immune Thrombocytopenia Purpura
Immune Thrombocytopenia PurpuraImmune Thrombocytopenia Purpura
Immune Thrombocytopenia Purpuraspa718
 
Role of Apalutamide in management of M0 CRPC
Role of Apalutamide in management of M0 CRPCRole of Apalutamide in management of M0 CRPC
Role of Apalutamide in management of M0 CRPCMohamed Abdulla
 

Tendances (20)

Locally Advanced Nsclc
Locally Advanced NsclcLocally Advanced Nsclc
Locally Advanced Nsclc
 
Prostate cancer asco 2020 updates
Prostate cancer asco 2020 updatesProstate cancer asco 2020 updates
Prostate cancer asco 2020 updates
 
Targetted agents in head and neck cancers
Targetted agents in head and neck cancersTargetted agents in head and neck cancers
Targetted agents in head and neck cancers
 
NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimoda...
NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimoda...NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimoda...
NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimoda...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
Multimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii NsclcMultimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii Nsclc
 
Slide deck updates on cml (1)
Slide deck updates on cml (1)Slide deck updates on cml (1)
Slide deck updates on cml (1)
 
Apalutamide
Apalutamide Apalutamide
Apalutamide
 
Management of advanced prostate carcinoma
Management of advanced prostate carcinomaManagement of advanced prostate carcinoma
Management of advanced prostate carcinoma
 
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
 
New in management of hormone sensitive prostate cancer
New in management of  hormone sensitive prostate cancerNew in management of  hormone sensitive prostate cancer
New in management of hormone sensitive prostate cancer
 
Role of Chemotherapy, Targeted therapy and Immunotherapy in NSCLC (Part II)
Role of Chemotherapy, Targeted therapy and Immunotherapy in NSCLC (Part II)Role of Chemotherapy, Targeted therapy and Immunotherapy in NSCLC (Part II)
Role of Chemotherapy, Targeted therapy and Immunotherapy in NSCLC (Part II)
 
Immunotherapy maintenence for advanced urothelial cancer
Immunotherapy maintenence for advanced urothelial cancerImmunotherapy maintenence for advanced urothelial cancer
Immunotherapy maintenence for advanced urothelial cancer
 
Her2 ebc webinar
Her2 ebc webinarHer2 ebc webinar
Her2 ebc webinar
 
Astro annual meeting 2014 highlights
Astro annual meeting 2014 highlightsAstro annual meeting 2014 highlights
Astro annual meeting 2014 highlights
 
Gut talk
Gut talkGut talk
Gut talk
 
Cco Gi 2008 Cr Slideset
Cco Gi 2008 Cr SlidesetCco Gi 2008 Cr Slideset
Cco Gi 2008 Cr Slideset
 
Advances in Immunotherapy for Non-Small Cell Lung Cancer
Advances in Immunotherapy for Non-Small Cell Lung CancerAdvances in Immunotherapy for Non-Small Cell Lung Cancer
Advances in Immunotherapy for Non-Small Cell Lung Cancer
 
Immune Thrombocytopenia Purpura
Immune Thrombocytopenia PurpuraImmune Thrombocytopenia Purpura
Immune Thrombocytopenia Purpura
 
Role of Apalutamide in management of M0 CRPC
Role of Apalutamide in management of M0 CRPCRole of Apalutamide in management of M0 CRPC
Role of Apalutamide in management of M0 CRPC
 

Similaire à 10 Antiangiogenicos en Cáncer de Pulmón

Treatment Of Potentially Resectable Pancreatic Cancer
Treatment Of Potentially Resectable Pancreatic CancerTreatment Of Potentially Resectable Pancreatic Cancer
Treatment Of Potentially Resectable Pancreatic Cancerfondas vakalis
 
Nivolumab vs Docetaxel in Lung SCC
Nivolumab vs Docetaxel in Lung SCCNivolumab vs Docetaxel in Lung SCC
Nivolumab vs Docetaxel in Lung SCCAbdelrahman Labban
 
CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...
CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...
CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...mutahir2
 
ADJUVANT RADIATION IN CA GALLBLADDER
ADJUVANT RADIATION IN CA GALLBLADDERADJUVANT RADIATION IN CA GALLBLADDER
ADJUVANT RADIATION IN CA GALLBLADDERMUNEER khalam
 
pitutary management
pitutary management pitutary management
pitutary management PRARABDH95
 
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer  BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer European School of Oncology
 
RADIOTHERAPY IN CARCINOMA OVARY
RADIOTHERAPY IN CARCINOMA OVARYRADIOTHERAPY IN CARCINOMA OVARY
RADIOTHERAPY IN CARCINOMA OVARYDR DEBASHIS PANDA
 
lung cancer: sclc uPTODATE.pptx
 lung cancer: sclc uPTODATE.pptx lung cancer: sclc uPTODATE.pptx
lung cancer: sclc uPTODATE.pptxDr. Sumit KUMAR
 
management of advanced cervical cancer [Autosaved].pptx
management of advanced cervical cancer [Autosaved].pptxmanagement of advanced cervical cancer [Autosaved].pptx
management of advanced cervical cancer [Autosaved].pptxSonyNanda2
 
Gastric cancer management
Gastric cancer managementGastric cancer management
Gastric cancer managementNabeel Yahiya
 
BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC
BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC
BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC European School of Oncology
 
Canadian Conference on Lymphoproliferative Disorders (CCOLD)
Canadian Conference on Lymphoproliferative Disorders (CCOLD)Canadian Conference on Lymphoproliferative Disorders (CCOLD)
Canadian Conference on Lymphoproliferative Disorders (CCOLD)Laurie Watkins
 

Similaire à 10 Antiangiogenicos en Cáncer de Pulmón (20)

Erbitux
ErbituxErbitux
Erbitux
 
Hodgkin chemo final
Hodgkin chemo finalHodgkin chemo final
Hodgkin chemo final
 
Journal club
Journal clubJournal club
Journal club
 
Treatment Of Potentially Resectable Pancreatic Cancer
Treatment Of Potentially Resectable Pancreatic CancerTreatment Of Potentially Resectable Pancreatic Cancer
Treatment Of Potentially Resectable Pancreatic Cancer
 
Nivolumab vs Docetaxel in Lung SCC
Nivolumab vs Docetaxel in Lung SCCNivolumab vs Docetaxel in Lung SCC
Nivolumab vs Docetaxel in Lung SCC
 
CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...
CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...
CORALLEEN phase 2 trial: Neoadjuvant Ribociclib plus Letrozole in Early Stage...
 
Khant zaw aung
Khant zaw aungKhant zaw aung
Khant zaw aung
 
ADJUVANT RADIATION IN CA GALLBLADDER
ADJUVANT RADIATION IN CA GALLBLADDERADJUVANT RADIATION IN CA GALLBLADDER
ADJUVANT RADIATION IN CA GALLBLADDER
 
NACTRT in stomach cancers
NACTRT in stomach cancersNACTRT in stomach cancers
NACTRT in stomach cancers
 
Cross trial
Cross trialCross trial
Cross trial
 
pitutary management
pitutary management pitutary management
pitutary management
 
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer  BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
 
Tnbc 2018 update
Tnbc 2018 updateTnbc 2018 update
Tnbc 2018 update
 
RADIOTHERAPY IN CARCINOMA OVARY
RADIOTHERAPY IN CARCINOMA OVARYRADIOTHERAPY IN CARCINOMA OVARY
RADIOTHERAPY IN CARCINOMA OVARY
 
Current Concepts in Chemotherapy for Head and Neck Cancer
Current Concepts in Chemotherapy for Headand Neck CancerCurrent Concepts in Chemotherapy for Headand Neck Cancer
Current Concepts in Chemotherapy for Head and Neck Cancer
 
lung cancer: sclc uPTODATE.pptx
 lung cancer: sclc uPTODATE.pptx lung cancer: sclc uPTODATE.pptx
lung cancer: sclc uPTODATE.pptx
 
management of advanced cervical cancer [Autosaved].pptx
management of advanced cervical cancer [Autosaved].pptxmanagement of advanced cervical cancer [Autosaved].pptx
management of advanced cervical cancer [Autosaved].pptx
 
Gastric cancer management
Gastric cancer managementGastric cancer management
Gastric cancer management
 
BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC
BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC
BALKAN MCO 2011 - A. Eniu - How to optimize systemic therapy in LABC
 
Canadian Conference on Lymphoproliferative Disorders (CCOLD)
Canadian Conference on Lymphoproliferative Disorders (CCOLD)Canadian Conference on Lymphoproliferative Disorders (CCOLD)
Canadian Conference on Lymphoproliferative Disorders (CCOLD)
 

Plus de Effyciens Marketing Online SL.

09 Tratamiento combinado de quimio y radioterapia en Cáncer de Pulmón
09 Tratamiento combinado de quimio y radioterapia en Cáncer de Pulmón09 Tratamiento combinado de quimio y radioterapia en Cáncer de Pulmón
09 Tratamiento combinado de quimio y radioterapia en Cáncer de PulmónEffyciens Marketing Online SL.
 
03 Diagnóstico y estadificación del Cáncer de Pulmón
03 Diagnóstico y estadificación del Cáncer de Pulmón03 Diagnóstico y estadificación del Cáncer de Pulmón
03 Diagnóstico y estadificación del Cáncer de PulmónEffyciens Marketing Online SL.
 

Plus de Effyciens Marketing Online SL. (14)

Glosario del Cáncer
Glosario del CáncerGlosario del Cáncer
Glosario del Cáncer
 
Programa III Jornada GIDO 2013
Programa III Jornada GIDO 2013Programa III Jornada GIDO 2013
Programa III Jornada GIDO 2013
 
Estudios de Usabilidad Web
Estudios de Usabilidad WebEstudios de Usabilidad Web
Estudios de Usabilidad Web
 
13 Inmunoterapia Cáncer de Pulmón
13 Inmunoterapia Cáncer de Pulmón13 Inmunoterapia Cáncer de Pulmón
13 Inmunoterapia Cáncer de Pulmón
 
09 Tratamiento combinado de quimio y radioterapia en Cáncer de Pulmón
09 Tratamiento combinado de quimio y radioterapia en Cáncer de Pulmón09 Tratamiento combinado de quimio y radioterapia en Cáncer de Pulmón
09 Tratamiento combinado de quimio y radioterapia en Cáncer de Pulmón
 
08 Radioterapia en Cáncer de Pulmón
08 Radioterapia en Cáncer de Pulmón08 Radioterapia en Cáncer de Pulmón
08 Radioterapia en Cáncer de Pulmón
 
07 Cirugía del Cáncer de Pulmón
07 Cirugía del Cáncer de Pulmón07 Cirugía del Cáncer de Pulmón
07 Cirugía del Cáncer de Pulmón
 
06 Cancer Microcítico de Pulmón
06 Cancer Microcítico de Pulmón06 Cancer Microcítico de Pulmón
06 Cancer Microcítico de Pulmón
 
05 Mesotelioma pleural maligno y timoma
05 Mesotelioma pleural maligno y timoma05 Mesotelioma pleural maligno y timoma
05 Mesotelioma pleural maligno y timoma
 
04 Biologia molecular en Cáncer de Pulmón
04 Biologia molecular en Cáncer de Pulmón04 Biologia molecular en Cáncer de Pulmón
04 Biologia molecular en Cáncer de Pulmón
 
14 Conclusiones: De Sidney a Denver
14 Conclusiones: De Sidney a Denver14 Conclusiones: De Sidney a Denver
14 Conclusiones: De Sidney a Denver
 
03 Diagnóstico y estadificación del Cáncer de Pulmón
03 Diagnóstico y estadificación del Cáncer de Pulmón03 Diagnóstico y estadificación del Cáncer de Pulmón
03 Diagnóstico y estadificación del Cáncer de Pulmón
 
02 Epidemiologia, screening y prevencion
02 Epidemiologia, screening y prevencion02 Epidemiologia, screening y prevencion
02 Epidemiologia, screening y prevencion
 
01 Introducción de Amsterdam a Sidney
01 Introducción de Amsterdam a Sidney01 Introducción de Amsterdam a Sidney
01 Introducción de Amsterdam a Sidney
 

Dernier

Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...DUY NGUYEN PHUC
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxTina Purnat
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhanthesalberry
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyYves Sucaet
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsPradnya Wadekar
 
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN              .pdfSGK VIÊM KHỚP DẠNG THẤP YHN              .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN .pdfHongBiThi1
 
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxRajendra Dev Bhatt
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptKavitha Krishnan
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...JakeMatthews12
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomSudhir Kumar
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptxRajendra Dev Bhatt
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptxnakera38
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionZeinabEmad3
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Ahmad Thanin
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxsiddharthroy26587
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisAshishMaletha2
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, PDr.Shalu Jain
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxAbdirahmanWaseem
 

Dernier (20)

Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptx
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhan
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathology
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractions
 
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN              .pdfSGK VIÊM KHỚP DẠNG THẤP YHN              .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
 
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptx
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), Addiction
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)
 
Oral disorders .pptx
Oral disorders .pptxOral disorders .pptx
Oral disorders .pptx
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth Analysis
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, P
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptx
 

10 Antiangiogenicos en Cáncer de Pulmón

  • 1. Tratamientos sistémicos en el NSCLC ANTIANGIOGÉNICOS Dr J Pérez Altozano HGU Elche / H Vega Baja Orihuela 8 de noviembre de 2013
  • 2. History of Therapy in Advanced NSCLC: FDA Approval Dates Gefitinib 2003 Docetaxel 2002 Standard therapies First line Second line Third line Maintenance Not approved Cisplatin 1978 Carboplatin 1989 BSC Paclitaxel Gemcitabine 1998 Bevacizumab 2006 Pemetrexed 2008/2009 Vinorelbine 1994 12+ Median OS (mos) ~ 8-10 ~6 ~ 2-4 1970 Erlotinib Pemetrexed 2004 Docetaxel 1999 1980 Single-agent platinum 1990 2000 Bevacizumab + PC Doublets Histology-directed therapy 1. FDA Web site. 2. NCCN. Clinical practice guidelines in oncology. v.3.2011. 3. Schrump, et al. Non-small cell lung cancer. In: Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
  • 3. Incidence of NSCLC Histologic Subtypes 20% 40% 15% 30% Adenocarcinoma Squamous-cell carcinoma Large-cell carcinoma NOS
  • 4. Lung Cancer Molecular Consortium Analysis in Lung Adenocarcinomas No Mutation Detected AKT1 NRAS MEK1 MET AMP HER2 PIK3CA 2% BRAF 2% Double Mutants 3% EML4-AKL 7% KRAS 22% EGFR 17% Kris MG, et al. ASCO 2011. CRA7506. Johnson BE, et al. IASLC WCLC 2011. Abstract O16.01
  • 6. Index • Bevacizumab • Antiangiogenic TKIs • Upcoming targeted therapies
  • 27. Background Evaluate the feasibility of induction combination therapy with cisplatin, pemetrexed and bevacizumab followed by surgery in patients with clinical stage II/IIIA nonsquamous NSCLC. Methods Induction chemotherapy : 3 cycles of cisplatin (75 mg/m2), pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) on Day 1, every 21 days. Patients underwent surgical resection at least 6 weeks after the last administration of bevacizumab, Primary endpoint: complete resection rate after the completion of three cycles of induction chemotherapy. Feasibility: complete resection rate 80% (24/30) or more. Results 6 institutions in Japan, June 2010 - November 2012. 31 patients were recruited, 30 of which were eligible. Median age was 64 years (range: 54-71). Adenocarcinoma/large cell carcinoma ratio: 30/0 Clinical stage IIA/IIB/IIIA ratio: 5/3/22. Grade 3 toxicities: Neutropenia (7%), nausea (7%), appetite loss (13%), hypertension (23%) and pulmonary embolism (3%). 27 (90%) patients completed three cycles at the full dose of chemotherapy. CR in 0%, PR in 37%, SD in 50% and PD in 10%. Disease control rate (CR+PR+SD) 87%. Five patients dropped out from the study before surgery. Complete resection rate after the completion of three cycles of induction chemotherapy: 83% (25/80). Conclusion Induction chemotherapy using a combination of cisplatin, pemetrexed and bevacizumab in patients with resectable clinical stage II/IIIA nonsquamous NSCLC is therefore considered to be a feasible treatment modality.
  • 28. Background Evaluate the feasibility of induction combination therapy with cisplatin, pemetrexed and bevacizumab followed by surgery in patients with clinical stage II/IIIA nonsquamous NSCLC. Methods Induction chemotherapy : 3 cycles of cisplatin (75 mg/m2), pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) on Day 1, every 21 days. Patients underwent surgical resection at least 6 weeks after the last administration of bevacizumab, Primary endpoint: complete resection rate after the completion of three cycles of induction chemotherapy. Feasibility: complete resection rate 80% (24/30) or more. Results 6 institutions in Japan, June 2010 - November 2012. 31 patients were recruited, 30 of which were eligible. Median age was 64 years (range: 54-71). Adenocarcinoma/large cell carcinoma ratio: 30/0 Clinical stage IIA/IIB/IIIA ratio: 5/3/22. Grade 3 toxicities: Neutropenia (7%), nausea (7%), appetite loss (13%), hypertension (23%) and pulmonary embolism (3%). 27 (90%) patients completed three cycles at the full dose of chemotherapy. CR in 0%, PR in 37%, SD in 50% and PD in 10%. Disease control rate (CR+PR+SD) 87%. Five patients dropped out from the study before surgery. Complete resection rate after the completion of three cycles of induction chemotherapy: 83% (25/80). Conclusion Induction chemotherapy using a combination of cisplatin, pemetrexed and bevacizumab in patients with resectable clinical stage II/IIIA nonsquamous NSCLC is therefore considered to be a feasible treatment modality.
  • 29. Background Explore the role of bevacizumab in the neoadjuvant setting. Assess the safety and efficacy of neoadjuvant bevacizumab plus pemetrexed and carboplatin followed by surgery in conventionally unresectable, locally advanced (III A-bulky N2, III B) lung adenocarcinoma. Methods Single-center, single-arm, phase II study investigates neoadjuvant bevacizumab (7.5mg/kg) plus pemetrexed (500 mg/m2) and carboplatin (AUC=5) x 4 cycles followed by surgery scheduled 3-4 weeks after last neoadjuvant therapy. Primary and secondary endpoints were resectability rate and perioperative complications. Results 20 patients were enrolled. Neoadjuvant-related toxicities: Epistaxis (5%), fatigue (30%), infusion reaction (5%), nausea (5%), diarrhea (10%), insomnia (5%), headache (5%); neutropenia (25%), anemia (10%), thrombocytopenia (5%). Grade > 3 toxicities: Fatigue (10%); neutropenia (5%), thrombocytopenia (5%). CR in 1 patient, PR in 8, SD in 10 and PD in 1. 14 (70%) patients underwent surgery. Median time between last neoadjuvant therapy and surgery: 25 days (22-28). R0 resection achieved in 10 patients. Postoperative complications were manageable. Conclusion The treatment modality of neoadjuvant bevacizumab plus pemetrexed and carboplatin followed by surgery appears to be safe and feasible in patients with unresectable, locally advanced (III A-bulky N2, III B) lung adenocarcinoma.
  • 30. Background Explore the role of bevacizumab in the neoadjuvant setting. Assess the safety and efficacy of neoadjuvant bevacizumab plus pemetrexed and carboplatin followed by surgery in conventionally unresectable, locally advanced (III A-bulky N2, III B) lung adenocarcinoma. Methods Single-center, single-arm, phase II study investigates neoadjuvant bevacizumab (7.5mg/kg) plus pemetrexed (500 mg/m2) and carboplatin (AUC=5) x 4 cycles followed by surgery scheduled 3-4 weeks after last neoadjuvant therapy. Primary and secondary endpoints were resectability rate and perioperative complications. Results 20 patients were enrolled. Neoadjuvant-related toxicities: Epistaxis (5%), fatigue (30%), infusion reaction (5%), nausea (5%), diarrhea (10%), insomnia (5%), headache (5%); neutropenia (25%), anemia (10%), thrombocytopenia (5%). Grade > 3 toxicities: Fatigue (10%); neutropenia (5%), thrombocytopenia (5%). CR in 1 patient, PR in 8, SD in 10 and PD in 1. 14 (70%) patients underwent surgery. Median time between last neoadjuvant therapy and surgery: 25 days (22-28). R0 resection achieved in 10 patients. Postoperative complications were manageable. Conclusion The treatment modality of neoadjuvant bevacizumab plus pemetrexed and carboplatin followed by surgery appears to be safe and feasible in patients with unresectable, locally advanced (III A-bulky N2, III B) lung adenocarcinoma.
  • 31. Background Two combination chemotherapy regimens were compared in a Phase 3, randomized, open-label United States only study Methods Stage IV chemonaïve non-squamous NSCLC. PemC (n=182) or PCB (n=179). Safety data compared for patients who received ≥1 dose of study treatment (PemC:171; PCB:166), and resource use including concomitant medications, transfusions, and hospitalizations was recorded. Results PemC experienced significantly more drug-related Grade 3/4 anemia (18.7% vs. 5.4%; p<0.001), Grade 3/4 thrombocytopenia (24.0% vs. 9.6%; p<0.001), and Grade 1/2 nausea (46.8% vs. 28.9%; p<0.001) PCB experienced significantly more drug-related Grade 3/4 neutropenia (24.6% vs. 48.8%; p<0.001) and Grade 1/2 alopecia (8.2% vs. 28.3%; p<0.001). Patients on PemC required more red blood cell (RBC) transfusions (34.5% vs. 11.4%; p<0.001). Erythropoietic stimulating agents (ESAs) were used more frequently (19.9% vs. 7.2%; p<0.001) in PemC. Granulocyte colony-stimulating factor (G-CSF) use was significantly higher with PCB (17.0% vs. 30.1%; p=0.005). Conclusion Mild-to-moderate nausea more common for PemC and alopecia, infection and neuropathy more frequent for PCB. Hospitalizations did not differ between treatments. ESAs and RBC transfusions were more common with PemC, and G-CSF use was more common with PCB.
  • 32. Background Two combination chemotherapy regimens were compared in a Phase 3, randomized, open-label United States only study Methods Stage IV chemonaïve non-squamous NSCLC. PemC (n=182) or PCB (n=179). Safety data compared for patients who received ≥1 dose of study treatment (PemC:171; PCB:166), and resource use including concomitant medications, transfusions, and hospitalizations was recorded. Results PemC experienced significantly more drug-related Grade 3/4 anemia (18.7% vs. 5.4%; p<0.001), Grade 3/4 thrombocytopenia (24.0% vs. 9.6%; p<0.001), and Grade 1/2 nausea (46.8% vs. 28.9%; p<0.001) PCB experienced significantly more drug-related Grade 3/4 neutropenia (24.6% vs. 48.8%; p<0.001) and Grade 1/2 alopecia (8.2% vs. 28.3%; p<0.001). Patients on PemC required more red blood cell (RBC) transfusions (34.5% vs. 11.4%; p<0.001). Erythropoietic stimulating agents (ESAs) were used more frequently (19.9% vs. 7.2%; p<0.001) in PemC. Granulocyte colony-stimulating factor (G-CSF) use was significantly higher with PCB (17.0% vs. 30.1%; p=0.005). Conclusion Mild-to-moderate nausea more common for PemC and alopecia, infection and neuropathy more frequent for PCB. Hospitalizations did not differ between treatments. ESAs and RBC transfusions were more common with PemC, and G-CSF use was more common with PCB.
  • 33. Background Two combination chemotherapy regimens were compared in a Phase 3, randomized, open-label United States only study Methods Stage IV chemonaïve non-squamous NSCLC. PemC (n=182) or PCB (n=179). Safety data compared for patients who received ≥1 dose of study treatment (PemC:171; PCB:166), and resource use including concomitant medications, transfusions, and hospitalizations was recorded. Results PemC experienced significantly more drug-related Grade 3/4 anemia (18.7% vs. 5.4%; p<0.001), Grade 3/4 thrombocytopenia (24.0% vs. 9.6%; p<0.001), and Grade 1/2 nausea (46.8% vs. 28.9%; p<0.001) PCB experienced significantly more drug-related Grade 3/4 neutropenia (24.6% vs. 48.8%; p<0.001) and Grade 1/2 alopecia (8.2% vs. 28.3%; p<0.001). Patients on PemC required more red blood cell (RBC) transfusions (34.5% vs. 11.4%; p<0.001). Erythropoietic stimulating agents (ESAs) were used more frequently (19.9% vs. 7.2%; p<0.001) in PemC. Granulocyte colony-stimulating factor (G-CSF) use was significantly higher with PCB (17.0% vs. 30.1%; p=0.005). Conclusion Mild-to-moderate nausea more common for PemC and alopecia, infection and neuropathy more frequent for PCB. Hospitalizations did not differ between treatments. ESAs and RBC transfusions were more common with PemC, and G-CSF use was more common with PCB.
  • 34. Background Designed on preclinical results suggesting additive interaction of metronomic chemotherapy with VEGF deprivation and EGFR inhibition, in term of anti-tumor/anti-angiogenic-activity and immune-modulation. Methods 35 inoperable NSCLC patients. 26 adenocarcinoma, 6 squamocellular and 3 NAS carcinoma. Median age of 68 years (range 3-75). Cisplatin (30mg/sqm days 1-3q21 + Etoposide 50mg/sqm days 1-15/21 + Bevacizumab 5mg/kg on the day 3q21. After 4 treatment courses, all patients who achieved a PR or SD received daily Erlotinib (150 mg/day), starting 1 week after end of chemotherapy until PD. Cytokine multiplex analysis and an immune-cytofluorimetric analysis after 4 bio-chemotherapy courses and 3 months after end of biochemotherapy. Results Significant decrease in serum levels of VEGF and IL-10 which was maintained along TKI treatment. No change in angiopoietin, interferon gamma, IL-12, PECAM and follistatin levels. During TKI maintenance we recorded an increase in IL-8 and leptine associated with a significant decrease in G-CSF levels and angiopoietin levels. Our immune-cytofluorimetric analysis of patients’ PBMCs showed a significant treatment-related increase in activated (CD3CD11C+CD14+CD80+CD83+) dendritic cells and activated (CD3+CD8+CD62L+) cytotoxic-T –lymphocytes. Conclusion Treatment strategy is safe and active in NSCLC patients, and is able to affects their systemic inflammatory status also inducing immunemodulation with potential antitumor.
  • 35. Background Designed on preclinical results suggesting additive interaction of metronomic chemotherapy with VEGF deprivation and EGFR inhibition, in term of anti-tumor/anti-angiogenic-activity and immune-modulation. Methods 35 inoperable NSCLC patients. 26 adenocarcinoma, 6 squamocellular and 3 NAS carcinoma. Median age of 68 years (range 3-75). Cisplatin (30mg/sqm days 1-3q21 + Etoposide 50mg/sqm days 1-15/21 + Bevacizumab 5mg/kg on the day 3q21. After 4 treatment courses, all patients who achieved a PR or SD received daily Erlotinib (150 mg/day), starting 1 week after end of chemotherapy until PD. Cytokine multiplex analysis and an immune-cytofluorimetric analysis after 4 bio-chemotherapy courses and 3 months after end of biochemotherapy. Results Significant decrease in serum levels of VEGF and IL-10 which was maintained along TKI treatment. No change in angiopoietin, interferon gamma, IL-12, PECAM and follistatin levels. During TKI maintenance we recorded an increase in IL-8 and leptine associated with a significant decrease in G-CSF levels and angiopoietin levels. Our immune-cytofluorimetric analysis of patients’ PBMCs showed a significant treatment-related increase in activated (CD3CD11C+CD14+CD80+CD83+) dendritic cells and activated (CD3+CD8+CD62L+) cytotoxic-T –lymphocytes. Conclusion Treatment strategy is safe and active in NSCLC patients, and is able to affects their systemic inflammatory status also inducing immunemodulation with potential antitumor.
  • 36. Background Frequent administration of low dose chemotherapy agents (metronomic chemotherapy [MC]) is thought to target endothelial cells of the tumor vasculature as well as tumor cells. Pilot phase 2 study: Bevacizumab and MC will result in enhanced antiangiogenic effect and clinical benefit in advanced NSCLC. Methods Untreated patients with stage 4 non-squamous NSCLC. 4-week cycle of paclitaxel (80 mg/m2 D1, 8, 15), gemcitabine (200-300 mg/m2 D1, 8, 15) and bevacizumab (10 mg/kg D1, 15) for 6 cycles. Patients without progressive disease received maintenance bevacizumab every 2 weeks. Primary endpoint: PFS with the goal to achieve a 30% improvement in the 6.4 months. Secondary endpoints: ORR, OS, safety and evaluation of potential biomarkers of angiogenesis. Results 33 evaluable patients were enrolled Median age 59 years. Grade 3 neutropenia (15%); grade 3 fatigue (6%); grade 3 nausea (3%); grade 3/4 hypertension (30%); grade 3/4 proteinuria (18%); pneumonitis (3 patients); and ischemic events (2 patients). Baseline biomarkers with significant correlation with response parameters: VEGF2 (ORR); PLGF (OS); angiopoietin -2 (PFS, OS); endocan (ORR); IL-8 (ORR, PFS); TGFβ-1 (ORR); thrombospondin-1 (ORR); and angiopoietin-1 (ORR). PFS: 9m (95% CI:7; 10), OS 30m (95% CI: 18; 37), 1-year survival rate 74%, 2-year survival rate 55%, ORR 73% (95% CI:0.54; 0.87) Conclusion MC with a platinum doublet in combination with bevacizumab is a feasible, tolerable, and active regimen in advanced nonsquamous NSCLC. Potential biomarkers were correlated with clinical outcome.
  • 37. Background Prospective phaseⅡ study to evaluate the efficacy and safety of bevacizumab in combination with carboplatin and paclitaxel(PCB) for EGFR-TKIs resistant Non-Sq NSCLC. Methods Multicenter phase II trial. Non-squamous NSCLC harboring EGFR gene mutation after failing EGFR-TKIs. Patients received carboplatin (AUC=6/5), paclitaxel (200mg/m2), bevacizumab (15mg/kg) intravenously on day1 every 3 weeks for three to six cycles, and bevacizumab every 3 weeks until disease progression or intolerable toxic effects. Primary endpoint: RR Secondary endpoints: PFS, OS, disease control rate and safety. Results 30 patients between March 2010 - February 2013. Median age: 60 years (45~74). EGFR mutation status exon19 del/exon21 L858R : 20/11. 1st line EGFR-TKIs gefitinib/erlotinib/other : 22/7/1. RR : 40% (95%CI:22%-58%). DCR : 83% (95%CI:70%-97%), PFS : 6.0 month (95%CI:4.8-12.2). Conclusion RR of 2nd line PCB therapy was lower than it was in 1st line phase II study of PCB in Japan, but same RR of E4599 study. We considered PCB therapy is one of the treatment option in 2nd-line for patient with EGFR-TKIs resistant Non-Sq NSCLC.
  • 38. Background Prospective phaseⅡ study to evaluate the efficacy and safety of bevacizumab in combination with carboplatin and paclitaxel(PCB) for EGFR-TKIs resistant Non-Sq NSCLC. Methods Multicenter phase II trial. Non-squamous NSCLC harboring EGFR gene mutation after failing EGFR-TKIs. Patients received carboplatin (AUC=6/5), paclitaxel (200mg/m2), bevacizumab (15mg/kg) intravenously on day1 every 3 weeks for three to six cycles, and bevacizumab every 3 weeks until disease progression or intolerable toxic effects. Primary endpoint: RR Secondary endpoints: PFS, OS, disease control rate and safety. Results 30 patients between March 2010 - February 2013. Median age: 60 years (45~74). EGFR mutation status exon19 del/exon21 L858R : 20/11. 1st line EGFR-TKIs gefitinib/erlotinib/other : 22/7/1. RR : 40% (95%CI:22%-58%). DCR : 83% (95%CI:70%-97%), PFS : 6.0 month (95%CI:4.8-12.2). Conclusion RR of 2nd line PCB therapy was lower than it was in 1st line phase II study of PCB in Japan, but same RR of E4599 study. We considered PCB therapy is one of the treatment option in 2nd-line for patient with EGFR-TKIs resistant Non-Sq NSCLC.
  • 39. Background Interim-analysis result of the BEST trial. Examines efficacy and safety of second- or third-line chemotherapy with erlotinib (E) and bevacizumab (B) for the Japanese patients (pts) with non-squamous, non-small cell lung cancer. Methods E 150 mg/day orally + B 15 mg/kg on the first day of each 3-week cycle. Primary endpoint: RR. Secondary endpoints: OS, PFS, disease control rate and incidence of adverse events. Planned to accrue 80 pts based on a two-stage design employing a binomial distribution with an alternative hypothesis response rate of 35% and a null hypothesis threshold response rate of 20%. Results 28 pts enrolled in 2 years. Median age: 67y (43-82). All had adenocarcinoma; 11 pts had EGFR mutation. 1 patient had stage IIIB, 23 pts had stage IV and 3 pts had recurrences after surgery. 21 pts received as second-line and 6 pts received as third-line chemotherapy. RR 18.5% (p=1.00; one-sided). DCR 77.8%, PFS 5.6 m; OS data not yet mature (median follow-up time was 11.9 m). Grade 3/4 non-hematologic toxicities: Acne (11.1%) and hypertension (11.1%). Significantly higher RR (p=0.02) and better PFS (p=0.03) in mutant group than in wild group. RR in mutant group was compared with 20% null hypothesis using the same binomial test (p=0.056). Conclusion Combination therapy of B + E had mild adverse effects but did not increase anti-cancer effect.
  • 40. Background Interim-analysis result of the BEST trial. Examines efficacy and safety of second- or third-line chemotherapy with erlotinib (E) and bevacizumab (B) for the Japanese patients (pts) with non-squamous, non-small cell lung cancer. Methods E 150 mg/day orally + B 15 mg/kg on the first day of each 3-week cycle. Primary endpoint: RR. Secondary endpoints: OS, PFS, disease control rate and incidence of adverse events. Planned to accrue 80 pts based on a two-stage design employing a binomial distribution with an alternative hypothesis response rate of 35% and a null hypothesis threshold response rate of 20%. Results 28 pts enrolled in 2 years. Median age: 67y (43-82). All had adenocarcinoma; 11 pts had EGFR mutation. 1 patient had stage IIIB, 23 pts had stage IV and 3 pts had recurrences after surgery. 21 pts received as second-line and 6 pts received as third-line chemotherapy. RR 18.5% (p=1.00; one-sided). DCR 77.8%, PFS 5.6 m; OS data not yet mature (median follow-up time was 11.9 m). Grade 3/4 non-hematologic toxicities: Acne (11.1%) and hypertension (11.1%). Significantly higher RR (p=0.02) and better PFS (p=0.03) in mutant group than in wild group. RR in mutant group was compared with 20% null hypothesis using the same binomial test (p=0.056). Conclusion Combination therapy of B + E had mild adverse effects but did not increase anti-cancer effect.
  • 41. Background Irinotecan and bevacizumab are effective against non-small cell lung cancer (NSCLC) and synergism with non-cross-resistance has been demonstrated in preclinical studies. Methods 24 patients having heavily treated metastatic NSCLC between March 2011 -November 2012. 16 patients had never been exposed to bevacizumab and 8 had received antiangiogenic therapy as part of their first-line (all had achieved a previous response for more than 6 months). 90-min intravenous infusion of 125 mg/m2 irinotecan on day 1 and 8 + 7.5 mg/kg bevacizumab on day 1 every 3 weeks. Results 1 patient (4.2%) CR, 6 (25%) PR. ORR 29.2% (4.6 months median response duration). 7 patients SD and DCR was 58.3%. PFS 4.8 months (95%CI 1.8-9.2) and OS 19.8 months (95%CI 9.2-30.2). Grade 3-4 neutropenia in 43% of patients and thrombocytopenia in 8.3%. 4 patients harbouring EGFR mutations had a long-lasting, partial response (>7 months after at least 4 prior lines). Conclusion Favourable activity and manageable toxicity profiles as third or fourth line. Regimen can represent a reasonable chemotherapeutic option, especially for subjects having EGFR mutations.
  • 42. Background Irinotecan and bevacizumab are effective against non-small cell lung cancer (NSCLC) and synergism with non-cross-resistance has been demonstrated in preclinical studies. Methods 24 patients having heavily treated metastatic NSCLC between March 2011 -November 2012. 16 patients had never been exposed to bevacizumab and 8 had received antiangiogenic therapy as part of their first-line (all had achieved a previous response for more than 6 months). 90-min intravenous infusion of 125 mg/m2 irinotecan on day 1 and 8 + 7.5 mg/kg bevacizumab on day 1 every 3 weeks. Results 1 patient (4.2%) CR, 6 (25%) PR. ORR 29.2% (4.6 months median response duration). 7 patients SD and DCR was 58.3%. PFS 4.8 months (95%CI 1.8-9.2) and OS 19.8 months (95%CI 9.2-30.2). Grade 3-4 neutropenia in 43% of patients and thrombocytopenia in 8.3%. 4 patients harbouring EGFR mutations had a long-lasting, partial response (>7 months after at least 4 prior lines). Conclusion Favourable activity and manageable toxicity profiles as third or fourth line. Regimen can represent a reasonable chemotherapeutic option, especially for subjects having EGFR mutations.
  • 43. Background Feasibility of BEV in NonSq-NSCLC patients who were previously treated with a platinum regimen. Methods Recurrent NonSq-NSCLC. VNR (25mg/kg on day 1, 8) + BEV (15mg/kg, day 1) every 3 weeks until PD. Primary endpoint: Feasibility. Secondary endpoints: Response rate and safety. Results June 2011 - January 2013 15 NSCLC patients. Median age: 68y (range 57-82). Median of 4 (range 1-12) cycles. Grade 3-4 neutropenia, anemia, thrombocytopenia and febrile neutropenia: 26.7%, 6.7%, 6.7%, and 13.3%. RR 26.7% and disease control rate 73.3%. PFS 2.8 months. Grade 3-4 phlebitis occurred in 3 patients. Conclusion VNR + BEV was safe and effective in NonSq-NSCLC patients who were previously treated with a platinum regimen.
  • 44. Background Feasibility of BEV in NonSq-NSCLC patients who were previously treated with a platinum regimen. Methods Recurrent NonSq-NSCLC. VNR (25mg/kg on day 1, 8) + BEV (15mg/kg, day 1) every 3 weeks until PD. Primary endpoint: Feasibility. Secondary endpoints: Response rate and safety. Results June 2011 - January 2013 15 NSCLC patients. Median age: 68y (range 57-82). Median of 4 (range 1-12) cycles. Grade 3-4 neutropenia, anemia, thrombocytopenia and febrile neutropenia: 26.7%, 6.7%, 6.7%, and 13.3%. RR 26.7% and disease control rate 73.3%. PFS 2.8 months. Grade 3-4 phlebitis occurred in 3 patients. Conclusion VNR + BEV was safe and effective in NonSq-NSCLC patients who were previously treated with a platinum regimen.
  • 45. Background Feasibility study of PEM plus BV as the first-line treatment for elderly advanced or recurrent non-Sq NSCLC. Methods Chemotherapy-naïve; unfit for bolus combination chemotherapy; stage III/IV or relapsed non-Sq NSCL. Age≥70; PS 0-1; no evidence of brain metastasis; no history of hemoptysis and irradiation for thorax. PEM (500mg/m2) + BV (15mg/kg) on day 1 every 3 weeks. Primary endpoint: Toxicity Secondary endpoints: ORR, PFS, OS and percentage of patients who completed more than 3 cycles. Results November 2010 -April 2012 12 patients. Median age: 78 y (72-81). Activating EGFR mutation No/Yes/unknown=9/2/1. Stage IIIB/IV/Recurrence=2/8/2. Grade 3≥ leukopenia (25%), neutropenia (25%), anemia (8%), thrombocytopenia (8%), febrile neutropenia (8%), anorexia (8%), hypertension (8%), fatigue (8%), nausea (8%), and perforation (colon) (8%). ORR 25%, PFS 5.6 (95% C.I. 1.1-7.9) and OS 10.3 months (95% C.I. 6.9-15.6 mo) in 11 evaluated patients. 1-year survival rate 49% (95% C.I. 12-79%). 7/12 pts (58%) received more than 3 cycles. Conclusion PEM +BV as first-line treatment for elderly non-Sq NSCLC was well tolerable and promising.
  • 46. Background Feasibility study of PEM plus BV as the first-line treatment for elderly advanced or recurrent non-Sq NSCLC. Methods Chemotherapy-naïve; unfit for bolus combination chemotherapy; stage III/IV or relapsed non-Sq NSCL. Age≥70; PS 0-1; no evidence of brain metastasis; no history of hemoptysis and irradiation for thorax. PEM (500mg/m2) + BV (15mg/kg) on day 1 every 3 weeks. Primary endpoint: Toxicity Secondary endpoints: ORR, PFS, OS and percentage of patients who completed more than 3 cycles. Results November 2010 -April 2012 12 patients. Median age: 78 y (72-81). Activating EGFR mutation No/Yes/unknown=9/2/1. Stage IIIB/IV/Recurrence=2/8/2. Grade 3≥ leukopenia (25%), neutropenia (25%), anemia (8%), thrombocytopenia (8%), febrile neutropenia (8%), anorexia (8%), hypertension (8%), fatigue (8%), nausea (8%), and perforation (colon) (8%). ORR 25%, PFS 5.6 (95% C.I. 1.1-7.9) and OS 10.3 months (95% C.I. 6.9-15.6 mo) in 11 evaluated patients. 1-year survival rate 49% (95% C.I. 12-79%). 7/12 pts (58%) received more than 3 cycles. Conclusion PEM +BV as first-line treatment for elderly non-Sq NSCLC was well tolerable and promising.
  • 48. Background A series of Japanese trials indicate docetaxel (DTX) monotherapy is a standard of care in elderly patients with advanced nonsmall cell lung cancer (NSCLC), and that the addition of platinum does not significantly improve the outcomes. BEV toxicity is a major concern for elderly patients. Methods Chemotherapy-naïve patients with advanced non-squamous NSCLC >70 year old ECOG PS 0/1 an DTX 60 (Level 0) or 50 (Level -1) mg/m2 and BEV 15 mg/kg on day 1, every 3 weeks. Primary endpoint: Toxicity Secondary endpoints: ORR, PFS, OS and completion rate of the 3 cycles of treatment. Results December 2010 - September 2012. 21 elderly patients (9 in level 0 and 12 in level -1). Median age: 75 years, 67% PS 1. Grade 3 or 4 of toxicities among all patients: Neutropenia (86%), anemia (5%), hypertension (19%), anorexia (10%), and increased aminotransferase levels (10%). 3/9 patients in level 0 and 3/11 patients in level -1 obtained PR. Completion rates of the 3 cycles of treatment :78% (7/9) in level 0 and 67 % (8/12) in level -1. Median PFS and OS: 5.4 and 11.1 months. Conclusion The recommended dose for this combination in future study is docetaxel 50 mg/m2 and bevacizumab 15mg/kg.
  • 49. Phase II trial: C (50 mg/m2), D (50 mg/m2), and B (10 mg/kg) every 2 weeks for up to 6 cycles, followed by B alone every 2 weeks until disease progression or unacceptable toxicity. Primary efficacy endpoint: PFS Secondary endpoints: Safety profile, ORR, disease control rate and OS 32 patients enrolled. Median age: 60 years (range 44-72; 28.1% > 65 years). Adenocarcinoma (%): 84. Median PFS: 6.4 months (95% CI, 4.2-8.7). Among the 22 patients evaluable for response: ORR 63.6% and DCR 95.4%. Combination: Bevacizumab (15 mg/kg), docetaxel (60 mg/m2) and carboplatin (AUC=6) on day 1 was administered every 3 weeks up to 6 cycles (induction phase). Bevacizumab maintenance therapy was performed until PD (maintenance phase). Primary endpoint: PFS to prove superiority to previous standard chemotherapy (docetaxel and cisplatin). 40 patients enrolled and 39 patients analyzed. Stage IV in 92%, EGFR mutations in 13% and unknown EGFR status in 8%. Median age: 62 years. Induction phase: 4 cycles in median (range: 1-6). 21 patients (54%) received maintenance phase with median 4 cycles (range: 2-24). ORR of 74% (26/35) and median PFS of 6.4 months (95% CI: 4.8-9.9).
  • 58. Background Evaluate the benefits and harms of AATKIs when added to chemotherapy for advanced NSCLC. Methods Systematic review of randomised controlled trials (RCTs) of AATKIs added to chemotherapy for advanced or metastatic NSCLC. Electronic databases (MEDLINE/PubMed, EMBASE, The Cochrane Library) + conference proceedings from ASCO, ESMO, IASLC WCLC and Clinical Trials Registries. Primary endpoint: OS. Secondary endpoints: PFS, ORR and (G≥3 CTCAE. Meta-analysis of the data was performed to obtain pooled hazard ratios (HR) for OS and PFS, and pooled odds ratios (OR) for ORR and G≥3CTCAE. Review Manager v5.2 software (Cochrane). Results 15 RCTs involving 7904 patients with advanced NSCLC. Overall population (N = 7904) Addition of AATKI to chemotherapy: Prolonged OS (HR 0.93; 95% confidence interval [CI] 0.88, 0.99; P=0.02) and PFS (HR 0.83; 95% CI 0.79, 0.88; P<0.00001). Increased ORR (OR 1.64, 95% CI 1.34, 2.02; P<0.00001) and G≥3CTCAEs (OR 1.78, 95% CI 1.41, 2.25; P<0.00001). First line (N = 3867), prolonged PFS (HR 0.86; 95% CI 0.79, 0.93; P<0.0001) but not OS (HR 0.96; 95% CI 0.89, 1.05; P=0.38). Second line (N=4037), prolonged both OS (HR 0.91; 95% CI 0.84, 0.98; P=0.02) and PFS (HR 0.80; 95% CI 0.74, 0.87; P<0.00001). Greatest OS benefit in patients with adenocarcinoma (HR 0.85; 95% CI 0.75, 0.96, P=0.01) and receiving docetaxel (HR 0.89; 95% CI 0.81, 0.98; P=0.02). Addition of AATKIs to second line pemetrexed did not improve OS (HR 0.95; 95% CI 0.79, 1.13; P=0.54) nor in patients with squamous histology (HR 1.01; 95% CI 0.87, 1.16; P=0.92). Conclusion The addition of AATKIs to chemotherapy in patients with advanced NSCLC prolongs OS, PFS and increases ORR, at the expense of increased toxicity. Greatest benefit is in second line, in adenocarcinomas and in patients receiving docetaxel.
  • 59. Background Sunitinib is an oral, selective multi-targeted tyrosine kinase inhibitor (TKI) with antiangiogenic and antitumor activities. Evaluate the efficacy and toxicity of this therapeutic strategy. Methods Retrospective review of 30 stage IV NSCLC patients who received sunitinib as salvage therapy in Shanghai Chest hospital, from January 2009 until August 2011. All patients previously treated with EGFR-TKIs. Results Median PFS: 1.25 months (95% CI: 0.90-1.9 months). Median OS: 3.40 months (95% CI: 3.00-6.80 months). Of the 29 patients eligible for efficacy evaluation, none PR. ECOG PS is predictive of both PFS (p=0.001) and OS (p<0.001). Hand-foot syndrome (53.3%), mucositis (40.0%), rash (36.7%) and diarrhea (33.3%) most commonly reported adverse events. Conclusion Sunitinib treatment did not demonstrate overall clinical benefits to the EGFR-TKI pretreated NSCLC Chinese patients.
  • 60. Background Sunitinib is an oral, selective multi-targeted tyrosine kinase inhibitor (TKI) with antiangiogenic and antitumor activities. Evaluate the efficacy and toxicity of this therapeutic strategy. Methods Retrospective review of 30 stage IV NSCLC patients who received sunitinib as salvage therapy in Shanghai Chest hospital, from January 2009 until August 2011. All patients previously treated with EGFR-TKIs. Results Median PFS: 1.25 months (95% CI: 0.90-1.9 months). Median OS: 3.40 months (95% CI: 3.00-6.80 months). Of the 29 patients eligible for efficacy evaluation, none PR. ECOG PS is predictive of both PFS (p=0.001) and OS (p<0.001). Hand-foot syndrome (53.3%), mucositis (40.0%), rash (36.7%) and diarrhea (33.3%) most commonly reported adverse events. Conclusion Sunitinib treatment did not demonstrate overall clinical benefits to the EGFR-TKI pretreated NSCLC Chinese patients.
  • 61. Background Sorafenib as well as mTOR inhibitors showed preliminary activity in KRAS mutated NSCLC. Methods Patients with relapsed solid tumors. Escalating doses of everolimus from 2.5-10.0 mg daily p.o. in a 14 days run-in phase  Combination with a fixed dose of sorafenib 400 mg bid p.o. KRAS mutation status is determined by PCR based high resolution melting curve analysis (HRM) on DNA extracted from FFPE material and validated using Sanger sequencing. Results 19 patients were recruited. DLT was not reached. MTD: 7.5 mg/day everolimus + 400 mg sorafenib. The best treatment outcome on day 57 was stable disease in 11 patients. Median PFS and OS were 3.7 and 5.5 months. The extension phase in KRAS mutated NSCLC is currently ongoing. Conclusion Treatment of patients with relapsed solid tumors with the combination of 7.5 mg everolimus p.o. daily + 400 mg sorafenib p.o. bid is safe and feasible. Current results of an extension phase in KRAS mutated NSCLC patients show preliminary clinical activity in this patient group with an unfavorable prognosis.
  • 62. Background Sorafenib as well as mTOR inhibitors showed preliminary activity in KRAS mutated NSCLC. Methods Patients with relapsed solid tumors. Escalating doses of everolimus from 2.5-10.0 mg daily p.o. in a 14 days run-in phase  Combination with a fixed dose of sorafenib 400 mg bid p.o. KRAS mutation status is determined by PCR based high resolution melting curve analysis (HRM) on DNA extracted from FFPE material and validated using Sanger sequencing. Results 19 patients were recruited. DLT was not reached. MTD: 7.5 mg/day everolimus + 400 mg sorafenib. The best treatment outcome on day 57 was stable disease in 11 patients. Median PFS and OS were 3.7 and 5.5 months. The extension phase in KRAS mutated NSCLC is currently ongoing. Conclusion Treatment of patients with relapsed solid tumors with the combination of 7.5 mg everolimus p.o. daily + 400 mg sorafenib p.o. bid is safe and feasible. Current results of an extension phase in KRAS mutated NSCLC patients show preliminary clinical activity in this patient group with an unfavorable prognosis.
  • 83. Background Motesanib is an orally administrated small molecule antagonist of VEGFR 1, 2, 3, and platelet-derived growth factor receptor (PDGFR), and stem cell factor receptor (c-kit). Methods Stage IV/recurrent non-squamous NSCLC patients without prior chemotherapy. Oral motesanib (125 mg) or placebo once daily in combination with paclitaxel (200 mg/m2) and carboplatin (AUC = 6) every 3 weeks up to 6 cycles and continue motesanib or placebo. ECOG PS 0-1 400 patients will be randomized in a double-blind 1:1 ratio to motesanib or placebo. Stratification factors: EGFR mutation status, weight loss of ≥ 5% in the previous 6 months, and region. Results First evaluation by IDMC performed using the data as of 26 December 2012. 63 patients (Japanese; median age, 64.5 y). All the blinded patients who received study treatment experienced AEs. Grade 3 to 5 AEs were reported in 38 patients (60.3%)  Alopecia (63.5%), peripheral sensory neuropathy (57.1%), and decreased appetite (50.8%). 7 patients had 8 serious AEs (SAEs)  cholecystitis, gastric ulcer haemorrhage, nausea, and upper gastrointestinal hemorrhage 1 treatment-related fatal AE (interstitial lung disease) Conclusion The first IDMC recommended continuation of the study after the review of unblinded data of 63 patients. Updated safety data will be presented after the second IDMC (JapicCTI-121887).